XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events
6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events

11. Subsequent Events

In August 2022, the Company signed amendment lease agreements for its future cell therapy manufacturing facility and company headquarters and for its existing facilities in South San Francisco, California. The amendments provide for approximately $15.0 million of additional tenant improvement allowances, in addition to the tenant improvement allowances of $25.2 million included in the original lease agreement. Additionally, the amendments increase the rent and term of the lease for some of the Company's existing facilities. As a result of the amendments, the Company expects the lease liability and corresponding right-of-use-asset to increase based on the present value of the remaining minimum rental payments using discount rates as of the effective date of the amendments. At this time, the amount of the increase to the lease liability and corresponding right-of-use-asset has not been determined but will be reflected in the condensed balance sheet as of September 30, 2022.